While small-capitalization biotechnology firms bring much potential to the table, they also represent a source of unpredictability. Nevertheless, for risk-takers, oncology specialist G1 Therapeutics (NASDAQ: GTHX ) appears quite enticing. First and foremost, it levers acumen in the burgeoning small-molecule therapeutics space.
Second, G1 Therapeutics stock seems undervalued for what speculators may be getting. Of course, to make the case that GTHX is a bullish idea, an investor must make two critical assumptions. First, experts in the small-molecule ecosystem must be reasonably accurate in terms of projected sector growth.
Second, the anticipated revenue haul of the biotech firm — helped perhaps by mitigated losses per share — must come to fruition. Otherwise, if those two assumptions fail, G1 Therapeutics stock may end up being like many other small-cap players: promising but falling short on the delivery component. Nevertheless, as a high-risk, high-reward idea, GTHX is a tempting proposition.
Therefore, under the context of speculation, I am bullish on the company. G1 Therapeutics Stock Benefits from an Attractive Valuation As humans, we tend to focus on price first and deal with the justification of the purchase later. So, with that in mind, let’s talk about the price.
Closing Friday’s session at $3.19 per share, G1 Therapeutics stock is “cheap” from a psychological perspective. However, that often leads to a temptation among many retail investors to buy up mo.